Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States

医学 脂肪肝 危险系数 内科学 疾病 比例危险模型 死亡风险 死因 死亡率 脂肪变性 置信区间
作者
Donghee Kim,Peter Konyn,Keeryth K. Sandhu,Brittany B. Dennis,Amanda Cheung,Aijaz Ahmed
出处
期刊:Journal of Hepatology [Elsevier]
卷期号:75 (6): 1284-1291 被引量:284
标识
DOI:10.1016/j.jhep.2021.07.035
摘要

•Metabolic dysfunction-associated fatty liver disease (MAFLD) was associated with increased all-cause and cardiovascular mortality. •NAFLD was associated with increased all-cause mortality among individuals with known metabolic risk factors. •Advanced fibrosis in MAFLD was associated with higher estimates for all-cause mortality than in NAFLD. Background & Aims Recently, international experts proposed redefining non-alcoholic fatty liver disease (NAFLD) as metabolic dysfunction-associated fatty liver disease (MAFLD), based on modified criteria. It is suspected that outcomes such as mortality may differ for these clinical entities. We studied the impact of MAFLD and NAFLD on all-cause and cause-specific mortality in US adults. Methods We analyzed data from 7,761 participants in the Third National Health and Nutrition Examination Survey and their linked mortality through 2015. NAFLD was diagnosed by ultrasonographic evidence of hepatic steatosis without other known liver diseases. MAFLD was defined based on the criteria proposed by an international expert panel. The Cox proportional hazard model was used to study all-cause mortality and cause-specific mortality between MAFLD and NAFLD, with adjustments for known risk factors. Results During a median follow-up of 23 years, individuals with MAFLD had a 17% higher risk of all-cause mortality (hazard ratio [HR] 1.17; 95% CI 1.04-1.32). Furthermore, MAFLD was associated with a higher risk of cardiovascular mortality. NAFLD per se did not increase the risk of all-cause mortality. Individuals who met both definitions had a higher risk of all-cause mortality (HR 1.13, 95% CI 1.00-1.26), while individuals who met the definition for MAFLD but not NAFLD had a 1.7-fold higher risk of all-cause mortality (HR 1.66, 95% CI 1.19-2.32). Estimates for all-cause mortality were higher for those with advanced fibrosis and MAFLD than for those with advanced fibrosis and NAFLD. Conclusions In this US population-based study, MAFLD was associated with an increased risk of all-cause mortality, while NAFLD demonstrated no association with all-cause mortality after adjusting for metabolic risk factors. Lay summary Our findings provide further support for the idea that non-alcoholic fatty liver disease (NAFLD) is a part of a broader multi-system disease that also includes obesity, diabetes, high blood pressure, and high cholesterol. Therefore, re-defining NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD) may help improve our understanding of predictors that increase the risk of death. Recently, international experts proposed redefining non-alcoholic fatty liver disease (NAFLD) as metabolic dysfunction-associated fatty liver disease (MAFLD), based on modified criteria. It is suspected that outcomes such as mortality may differ for these clinical entities. We studied the impact of MAFLD and NAFLD on all-cause and cause-specific mortality in US adults. We analyzed data from 7,761 participants in the Third National Health and Nutrition Examination Survey and their linked mortality through 2015. NAFLD was diagnosed by ultrasonographic evidence of hepatic steatosis without other known liver diseases. MAFLD was defined based on the criteria proposed by an international expert panel. The Cox proportional hazard model was used to study all-cause mortality and cause-specific mortality between MAFLD and NAFLD, with adjustments for known risk factors. During a median follow-up of 23 years, individuals with MAFLD had a 17% higher risk of all-cause mortality (hazard ratio [HR] 1.17; 95% CI 1.04-1.32). Furthermore, MAFLD was associated with a higher risk of cardiovascular mortality. NAFLD per se did not increase the risk of all-cause mortality. Individuals who met both definitions had a higher risk of all-cause mortality (HR 1.13, 95% CI 1.00-1.26), while individuals who met the definition for MAFLD but not NAFLD had a 1.7-fold higher risk of all-cause mortality (HR 1.66, 95% CI 1.19-2.32). Estimates for all-cause mortality were higher for those with advanced fibrosis and MAFLD than for those with advanced fibrosis and NAFLD. In this US population-based study, MAFLD was associated with an increased risk of all-cause mortality, while NAFLD demonstrated no association with all-cause mortality after adjusting for metabolic risk factors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
2秒前
小蘑菇应助忧心的雁采纳,获得10
2秒前
ccc发布了新的文献求助10
2秒前
feijelly完成签到,获得积分10
3秒前
史育川完成签到 ,获得积分10
4秒前
4秒前
orixero应助摆不烂采纳,获得10
7秒前
耶椰耶完成签到 ,获得积分10
7秒前
逐梦发布了新的文献求助10
8秒前
李洪晔完成签到,获得积分10
8秒前
blind发布了新的文献求助10
8秒前
8秒前
犹豫寒烟发布了新的文献求助10
8秒前
ccc完成签到,获得积分10
8秒前
李健的小迷弟应助冰阔罗采纳,获得10
9秒前
Dimple发布了新的文献求助10
9秒前
zhuguli完成签到,获得积分10
10秒前
ephore应助隐形世立采纳,获得30
10秒前
闫栋完成签到 ,获得积分10
11秒前
11秒前
小二郎应助侯天宇采纳,获得10
12秒前
敞敞亮亮完成签到 ,获得积分10
12秒前
Hello应助桔子不笑采纳,获得10
13秒前
ccc完成签到,获得积分10
15秒前
忧心的雁发布了新的文献求助10
16秒前
小二郎应助端庄书雁采纳,获得10
17秒前
阿a发布了新的文献求助20
17秒前
18秒前
nature发布了新的文献求助10
20秒前
20秒前
顾矜应助blind采纳,获得10
21秒前
3424923462发布了新的文献求助10
21秒前
澄明的晨星完成签到,获得积分10
22秒前
七分饱完成签到,获得积分10
23秒前
犹豫寒烟完成签到,获得积分10
23秒前
HJK发布了新的文献求助10
24秒前
liulei完成签到 ,获得积分10
25秒前
kk完成签到,获得积分10
25秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3163348
求助须知:如何正确求助?哪些是违规求助? 2814206
关于积分的说明 7903775
捐赠科研通 2473774
什么是DOI,文献DOI怎么找? 1317050
科研通“疑难数据库(出版商)”最低求助积分说明 631614
版权声明 602187